Vivitrol (naltrexone) is a prescription injectable medicine used to treat alcohol dependence and to prevent relapse to opioid dependence, after opioid detoxification.
Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
FDA approves injectable drug to treat opioid-dependent patients[ARCHIVED]
FDA press release (10/12/2010)
Vivitrol (naltrexone for extended-release injectable suspension): Medication Guide Required for Patients[ARCHIVED]
MedWatch alert (5/4/2010)
Information for Healthcare Professionals: Naltrexone Injection Site Reactions [naltrexone for extended-release injectable suspension (marketed as Vivitrol)][ARCHIVED]